142 related articles for article (PubMed ID: 35847956)
1. Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study.
Yang ZR; Su YD; Ma R; Wu HL; Li Y
Front Oncol; 2022; 12():811800. PubMed ID: 35847956
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Zhang G; Gong S; Pang L; Hou L; He W
Front Oncol; 2021; 11():659217. PubMed ID: 34012920
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W; Li Z; Zheng Z; Wu X
Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China.
Li F; Liao Z; Zhao J; Zhao G; Li X; Du X; Yang Y; Yang J
Oncotarget; 2017 Sep; 8(38):64471-64480. PubMed ID: 28969086
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.
Yu W; Zhang H; Chen J; Zhang X; Chen Y; Qu G; Huang G; Zhou Y; Ye T; Fan Z; Yao Y
Ann Transl Med; 2022 Sep; 10(18):981. PubMed ID: 36267741
[TBL] [Abstract][Full Text] [Related]
8. Apatinib mesylate tablet in the treatment of advanced malignant melanoma.
Yang L; Zhu H; Luo P; Chen S; Xu Y; Wang C
Onco Targets Ther; 2018; 11():5333-5338. PubMed ID: 30214239
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial.
Wang J; Huang D; Yang W; Song Q; Jia Y; Chen P; Cheng Y
Front Oncol; 2022; 12():1030798. PubMed ID: 36505785
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study.
Ren Y; Wang T; Cheng X; Ke G; Huang Y; Yang H; Huang X; Tian W; Wang H
Ann Transl Med; 2023 Jan; 11(2):106. PubMed ID: 36819505
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study.
Sun F; Lu S; Zhen Z; Zhu J; Wang J; Huang J; Zhang Y; Li H; Cai R; Liu M; Wu L; Sun X; Zhang Y
Cancer Manag Res; 2020; 12():6177-6185. PubMed ID: 32801866
[TBL] [Abstract][Full Text] [Related]
13. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study.
Li H; Zeng J; Jin X; Yu X; Zhou G; Hong W
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1083-1090. PubMed ID: 30937519
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
Li LH; Chen WC; Wu G
Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.
Wang X; Wang J; Sun B; Sun Y; Liu N; Niu X; Li C; Li L; Zhang Q; Hao J; Wang X
Ann Transl Med; 2022 Sep; 10(18):961. PubMed ID: 36267758
[TBL] [Abstract][Full Text] [Related]
16. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
17. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
18. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
Wang D; Yang X; Long J; Lin J; Mao J; Xie F; Wang Y; Wang Y; Xun Z; Bai Y; Yang X; Guan M; Pan J; Seery S; Sang X; Zhao H
Front Oncol; 2021; 11():646979. PubMed ID: 33912461
[TBL] [Abstract][Full Text] [Related]
19. Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer.
Su M; Gao Y; Ye X; Zhou Q; Zhao L; Cai X; Chen D; Su H; Zhang X; Xie C
Onco Targets Ther; 2019; 12():9707-9713. PubMed ID: 32009803
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
